These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 30621318)

  • 21. Hepatitis C viral kinetics: the past, present, and future.
    Chatterjee A; Smith PF; Perelson AS
    Clin Liver Dis; 2013 Feb; 17(1):13-26. PubMed ID: 23177280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of novel small molecule inhibitors against the NS3/4A protease of hepatitis C virus genotype 4a.
    El-Sayed SM; Ali MAM; El-Gendy BEM; Dandash SS; Issac Y; Saad R; Azab MM; Mohamed MR
    Curr Pharm Des; 2018; 24(37):4484-4491. PubMed ID: 30501598
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and effectiveness of direct acting antivirals for treatment of hepatitis C virus in patients with solid organ transplantation.
    Mansour M; Hill L; Kerr J
    Transpl Infect Dis; 2018 Dec; 20(6):e12972. PubMed ID: 30080955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Boceprevir, an NS3 protease inhibitor of HCV.
    Berman K; Kwo PY
    Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Application of direct antiviral drugs in special patients with HCV infection].
    Jiang C; Liu CY; Shao S; Gao YH
    Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):316-320. PubMed ID: 29996347
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct-acting agents for hepatitis C virus before and after liver transplantation.
    Sugawara Y; Hibi T
    Biosci Trends; 2018 Jan; 11(6):606-611. PubMed ID: 29238003
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Studying the Hepatitis C Virus-Induced Epigenetic Signature After Cure with Direct-Acting Antivirals.
    Perez S; Gal-Tanamy M
    Methods Mol Biol; 2019; 1911():191-207. PubMed ID: 30593627
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.
    Gentile I; Maraolo AE; Niola M; Graziano V; Borgia G; Paternoster M
    Expert Rev Gastroenterol Hepatol; 2016 Nov; 10(11):1227-1234. PubMed ID: 27607920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New drug targets for hepatitis C and other Flaviviridae viruses.
    Paula T; Pablo R; Eugenia V; Pablo B; Sabino P; José M; Antonio M; Dolores HM; Pablo L; Javier GS; Vincente S
    Infect Disord Drug Targets; 2009 Apr; 9(2):133-47. PubMed ID: 19275702
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Economic evaluation of the hepatitis C elimination strategy in Greece in the era of affordable direct-acting antivirals.
    Gountas I; Sypsa V; Papatheodoridis G; Souliotis K; Athanasakis K; Razavi H; Hatzakis A
    World J Gastroenterol; 2019 Mar; 25(11):1327-1340. PubMed ID: 30918426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries.
    Echeverría N; Betancour G; Gámbaro F; Hernández N; López P; Chiodi D; Sánchez A; Boschi S; Fajardo A; Sóñora M; Moratorio G; Cristina J; Moreno P
    Virus Res; 2016 Sep; 223():140-6. PubMed ID: 27449600
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PK/PD and antiviral activity of anti-HCV therapy: is there still a role in the choice of treatment?
    Zuccaro V; Lombardi A; Asperges E; Sacchi P; Bruno R
    Expert Opin Drug Metab Toxicol; 2020 Feb; 16(2):97-101. PubMed ID: 32003256
    [No Abstract]   [Full Text] [Related]  

  • 34. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
    Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
    HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current race in the development of DAAs (direct-acting antivirals) against HCV.
    De Clercq E
    Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antiviral agents for analyzing virus life cycle: chemical genetics for virology].
    Watashi K
    Yakugaku Zasshi; 2013; 133(11):1169-75. PubMed ID: 24189558
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New HCV therapies on the horizon.
    Vermehren J; Sarrazin C
    Clin Microbiol Infect; 2011 Feb; 17(2):122-34. PubMed ID: 21087349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
    Pol S; Parlati L
    Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of chronic hepatitis C: current and future.
    Pawlotsky JM
    Curr Top Microbiol Immunol; 2013; 369():321-42. PubMed ID: 23463207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.